ALLO
Price
$1.69
Change
-$0.04 (-2.31%)
Updated
Sep 18 closing price
Capitalization
583.88M
40 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.70
Change
-$0.02 (-0.74%)
Updated
Sep 18 closing price
Capitalization
414.67M
51 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs EDIT

ALLO vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALLO vs. EDIT commentary
Sep 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and EDIT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($584M) has a higher market cap than EDIT($415M). EDIT YTD gains are higher at: 31.707 vs. ALLO (23.358). EDIT has higher annual earnings (EBITDA): -67.46M vs. ALLO (-152.53M). ALLO has more cash in the bank: 333M vs. EDIT (212M). EDIT has less debt than ALLO: EDIT (15.5M) vs ALLO (70.4M). EDIT has higher revenues than ALLO: EDIT (47M) vs ALLO (4.64M).
ALLOEDITALLO / EDIT
Capitalization584M415M141%
EBITDA-152.53M-67.46M226%
Gain YTD23.35831.70774%
P/E RatioN/AN/A-
Revenue4.64M47M10%
Total Cash333M212M157%
Total Debt70.4M15.5M454%
FUNDAMENTALS RATINGS
ALLO vs EDIT: Fundamental Ratings
ALLO
EDIT
OUTLOOK RATING
1..100
6012
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6153
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLO's Valuation (34) in the Biotechnology industry is in the same range as EDIT (35). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

ALLO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (99). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (53) in the Biotechnology industry is in the same range as ALLO (61). This means that EDIT’s stock grew similarly to ALLO’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that EDIT’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
COMPARISON
Comparison
Sep 19, 2026
Stock price -- (ALLO: $1.69 vs. EDIT: $2.70)
Brand notoriety: ALLO and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 260% vs. EDIT: 848%
Market capitalization -- ALLO: $583.88M vs. EDIT: $414.67M
ALLO [@Biotechnology] is valued at $583.88M. EDIT’s [@Biotechnology] market capitalization is $414.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green while EDIT’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ALLO and EDIT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 7 bearish.
  • EDIT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -5.06% price change this week, while EDIT (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.53%. For the same industry, the average monthly price growth was -8.46%, and the average quarterly price growth was +7.13%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 29, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+1.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALLO
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMBPX37.82N/A
N/A
Principal MidCap R5
MVSSX39.77N/A
N/A
Victory Integrity Small-Cap Value R6
ACWEX22.72N/A
N/A
Cavanal Hill World Energy & Power C
TPYRX8.46N/A
N/A
Touchstone Sands Capital Intl Gr Eq R6
FGIQX21.39-0.05
-0.23%
Nomura Growth and Income R6